Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.66 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 8/20 | 0.61 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257566 | 1.00 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL3827177 | 1.00 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL20825305 | 1.00 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL18257558 | 1.00 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL18257506 | 1.00 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL23616209 | 1.00 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL9551248 | 0.97 | REN (0.68) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL15255353 | 0.96 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL9551300 | 0.96 | REN (0.66) | RENCAPN1CTSKCTSLCTSS | |
| SCHEMBL4576421 | 0.94 | CTSK (0.65) | RENCAPN1CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812152-B | Synthesis and anti-inflammatory application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | claimed |
| CN-112794879-B | Synthesis and application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | claimed |
| CN-112794879-B | Synthesis and application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-112812152-B | Synthesis and anti-inflammatory application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | disclosed |
| EP-3297678-B1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LTD (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-10519197-B1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-07-30 | — | — | US | disclosed |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Laurus Labs Ltd. (IN) | 2019-03-21 | — | — | US | disclosed |
| WO-2016185450-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-5821331-A | INHIBIT THE PROTEOLYTIC ACTIVITY OF PROTEASES | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5514778-A | ENZYME INHIBITORS OF PROTEOLYTIC ENZYMES FOR RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0632051-A1 | Anti-picornaviral agents | ELI LILLY AND COMPANY (US) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PRCP, SF3B5, GBA1 | REN 22/4885CAPN1 546/4885CTSK 201/4885 |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | REN 17/4885CAPN1 603/4885CTSK 252/4885 |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | REN 17/4885CAPN1 603/4885CTSK 252/4885 |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | REN 592/4885CAPN1 276/4885CTSK 92/4885 |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | REN 754/4885CAPN1 259/4885CTSK 122/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | REN 976/4885CAPN1 199/4885CTSK 171/4885 |
| US-10519197-B1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | REN 1650/4885CAPN1 1207/4885CTSK 516/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | REN 17/4885CAPN1 603/4885CTSK 252/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | REN 826/4885CAPN1 242/4885CTSK 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.